New developments in autologous tumor cell vaccination therapy for renal cell carcinoma

2000 ◽  
Vol 2 (5) ◽  
pp. 369-371
Author(s):  
Alfons JM van den Eertwegh ◽  
Herbert M. Pinedo
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Autologous Tumor Cell ◽  
Autologous Tumor ◽  
New Developments ◽  
Vaccination Therapy

Autologous Tumor Cell Line–Derived Vaccine for Patient-Specific Treatment of Advanced Renal Cell Carcinoma

2004 ◽  
Vol 19 (5) ◽  
pp. 570-580 ◽  
Author(s):  
Robert Dillman ◽  
Neil Barth ◽  
Louis VanderMolen ◽  
Khosrow Mahdavi ◽  
Linda Beutel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Line ◽  
Renal Cell ◽  
Specific Treatment ◽  
Tumor Cell Line ◽  
Patient Specific ◽  
Autologous Tumor Cell ◽  
Autologous Tumor

Autologous Tumor Cell Line–Derived Vaccine for Patient-Specific Treatment of Advanced Renal Cell Carcinoma

2004 ◽  
Vol 19 (5) ◽  
pp. 570-580 ◽  
Author(s):  
Robert Dillman ◽  
Neil Barth ◽  
Louis VanderMolen ◽  
Khosrow Mahdavi ◽  
Linda Beutel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Line ◽  
Renal Cell ◽  
Specific Treatment ◽  
Tumor Cell Line ◽  
Patient Specific ◽  
Autologous Tumor Cell ◽  
Autologous Tumor

Treatment of Kidney Cancer with Autologous Tumor Cell Vaccines of Short-Term Cell Lines Derived from Renal Cell Carcinoma

2001 ◽  
Vol 16 (1) ◽  
pp. 47-54 ◽  
Author(s):  
Robert O. Dillman ◽  
Neil M. Barth ◽  
Louis A. VanderMolen ◽  
David H. Garfield ◽  
Cristina De Leon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Kidney Cancer ◽  
Renal Cell ◽  
Autologous Tumor Cell ◽  
Autologous Tumor ◽  
Short Term ◽  
Tumor Cell Vaccines

Treatment of advanced renal cell carcinoma with tumor lysate pulsed IL-12 secreting autologous dendritic cells

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14585-14585
Author(s):  
T. F. Wimpissinger ◽  
T. Felzmann ◽  
H. Hügel ◽  
P. Funovics ◽  
W. Stackl
Keyword(s):  
Renal Cell Carcinoma ◽  
Dendritic Cells ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Antigens ◽  
Advanced Renal Cell Carcinoma ◽  
Interleukin 12 ◽  
Autologous Tumor Cell ◽  
Autologous Tumor ◽  
Cancer Vaccination

14585 Background: We have conducted a clinical phase I trial to evaluate feasibility and safety of dendritic cell-based immunotherapy in patients with advanced renal cell carcinoma (RCC). As opposed to previous cancer vaccination studies, dendritic cells were specifically enabled to secrete interleukin 12 (IL-12). Methods: Patients with advanced RCC (n = 11) received six weekly intranodal vaccinations with autologous monocyte-derived dendritic cells (mDCs). MDCs were loaded with autologous tumor cell lysate and were specifically stimulated to secrete IL-12 to polarize type-1 T-helper lymphocytes (Th1) and to directly present tumor antigens to cytotoxic T lymphocytes (CTL). Results: There was no significant treatment-related toxicity and no clinical evidence of autoimmunity. Vaccination was very well tolerated. Five patients had stable disease for at least five months, while four patients had progressive disease. Two patients with early clinically significant disease progression had to be excluded before completion of the treatment. In addition, we could detect enhanced anti-tumor immunity in vitro comparing immune response before versus after cancer vaccination. Conclusions: Our findings indicate that cancer vaccination with IL-12 secreting mDCs is well tolerated and has potential clinical and clear immunological effects in patients with advanced RCC. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document